Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/tri.13414 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhaled Medications for Maintenance Therapy in Pediatric Noncystic Fibrosis Bronchiectasis.
Ann Pharmacother
September 2024
Department of Pharmacy, Riley Hospital for Children, Indiana University Health, Indianapolis, IN, USA.
Objective: This review focuses on evaluating literature for the use of inhaled mucolytics (hypertonic saline, mannitol, and dornase alfa), inhaled antibiotics (tobramycin, aztreonam, colistin, and amikacin), and inhaled corticosteroids in pediatric noncystic fibrosis bronchiectasis.
Data Sources: A literature search via PubMed was conducted using the search terms "non-cystic fibrosis bronchiectasis," "primary ciliary dyskinesia," and "bronchiectasis" in combination with each inhaled agent of interest.
Study Selection And Data Extraction: Studies were included if they were specific to patients with a clinical diagnosis of noncystic fibrosis bronchiectasis published from 1998 to July 2024.
Rib plating is a recommended intervention for patients with multiple rib fractures or flail chest to improve shortness of breath, significantly reduce pain, and shorten the length of hospital stay. Here, we report a unique and extremely rare finding in a patient with empyema following intrathoracic rib fixation. A 32-year-old male with a history of alcohol use disorder presented to the emergency department trauma bay after a motor vehicle accident.
View Article and Find Full Text PDFUse of dornase alfa in pediatric patients without cystic fibrosis.
Hosp Pract (1995)
April 2023
Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA, USA.
Objectives: Literature regarding clinical benefits of dornase alfa (DNase) in pediatric patients without cystic fibrosis is lacking. In December 2020, the study institution implemented restrictions to limit DNase use in this patient population. The primary objective was adherence to DNase ordering restrictions.
View Article and Find Full Text PDFIntrapleural Tissue Plasminogen Activator and Dornase Alfa Administration for a Multiloculated Recurrent Malignant Pleural Effusion: A Case Report.
Cureus
April 2022
Pulmonary and Critical Care, Arrowhead Regional Medical Center, Colton, USA.
Malignant pleural effusions (MPEs) can often be very difficult to manage despite conservative interventions including thoracentesis and indwelling pleural catheter placement. These effusions can be septated and loculated, leading to complexities in drainage and symptomatic relief for patients. As such, physicians have experimented with the use of tissue plasminogen activator (t-PA) and dornase alfa (DNase) in attempts to drain complex malignant pleural effusions.
View Article and Find Full Text PDFStudy protocol for DICE trial: Video-assisted thoracoscopic surgery decortication versus interventional radiology guided chest tube insertion for the management of empyema.
Contemp Clin Trials Commun
June 2021
Division of Thoracic Surgery, Department of Surgery, Queen's University, 76 Stuart Street, Kingston, ON, K7L 2V7, Canada.
Article Synopsis
- Empyema is a common condition involving pus in the pleural space, but there is no clear consensus on the best initial treatment method, which could include chest tube insertion with fibrinolytics or surgical decortication.
- A randomized control trial will compare these two management strategies for adult patients with empyema to determine their effectiveness in preventing further interventions within 30 days.
- The study will assess various outcomes, including re-intervention rates, size of empyema, length of hospital stay, and overall patient quality of life.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!